전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,045 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleWest China HospitalPhase 1

JWK010 gene therapy (JWK010 gene therapy)

Oculocutaneous Albinism (OCA) · Oculocutaneous Albinism (OCA)

#OculocutaneousAlbinismOCA#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
AntibodyLimited DatastaleKeythera Pharmaceuticals (Austr…Phase 1

atezolizumab (Tecentriq, KF-0210, KF-0210 (dosage RP2D) + Atezolizumab, dosage RP2D)

Advanced Solid Tumor; Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#ColorectalCancer+1
Trials 1Status Active
AntibodyLimited DatastaleKeythera Pharmaceuticals (Austr…Phase 1

atezolizumab (Tecentriq, KF-0210, dosage RP2D-1, KF-0210 (dosage RP2D-1) + Atezolizumab)

Advanced Solid Tumor; Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#ColorectalCancer+1
Trials 1Status Active
AntibodyLimited DatastaleKeythera Pharmaceuticals (Austr…Phase 1

atezolizumab (Tecentriq, KF-0210, dosage RP2D-2, KF-0210 (dosage RP2D-2) + Atezolizumab)

Advanced Solid Tumor; Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#ColorectalCancer+1
Trials 1Status Active
CGTLimited DatastaleRong TaoPhase 1

KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells） (KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）)

Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia With Failed Remission · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
AntibodyLimited DatastaleMalaria Research and Training C…Phase 2

VRC-MALMAB0114-00-AB (L9LS, L9LS (VRC-MALMAB0114-00-AB))

Plasmodium Falciparum Infection; Malaria · Plasmodium Falciparum Infection

#PlasmodiumFalciparumInfection#Antibody#Phase2#monoclonal-antibody#Malaria
Trials 1Status Active
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LCAR-B4822M CAR-T Cell Immunotherapy (LCAR-B4822M CAR-T Cell Immunotherapy)

Refractory or Relapsed Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LCAR-C182A cells (LCAR-C182A cells)

Gastric Cancer; Pancreatic Ductal Adenocarcinoma · Gastric Cancer

#GastricCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LCAR-C18S cells (LCAR-C18S cells)

Solid Tumors, Adult · Solid Tumors, Adult

#SolidTumorsAdult#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LCAR-G08 cells (LCAR-G08 cells)

Advanced Gastrointestinal Tumors · Advanced Gastrointestinal Tumors

#AdvancedGastrointestinalTumors#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
AntibodyLimited DatastaleShanghai Pulmonary Hospital, Sh…Phase 2

LM-108+Sintilimab (LM-108+Sintilimab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Shanghai
Trials 1Status Recruiting
AntibodyLimited DatastaleOslo University HospitalPhase 2

pembrolizumab (Keytruda, LTX-315 + pembrolizumab)

Melanoma Stage IIIB-IV · Melanoma Stage IIIB-IV

#MelanomaStageIIIB-IV#Antibody#Phase2#monoclonal-antibody#Oslo
Trials 1Status Recruiting
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LUCAR-20SP cells (LUCAR-20SP cells)

Relapsed B-cell Non-Hodgkin Lymphoma; Refractory B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LUCAR-G79 T cells (LUCAR-G79 T cells)

Relapsed/Refractory Autoimmune Diseases · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

LV20.19 CAR T cells (LV20.19 CAR T cells)

Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma · Non Hodgkin Lymphoma

#NonHodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleM.D. Anderson Cancer CenterPhase 1

LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide (LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide)

Metastatic Esophageal; Gastric Cancer · Metastatic Esophageal

#MetastaticEsophageal#Antibody#Phase1#monoclonal-antibody#GastricCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleM.D. Anderson Cancer CenterPhase 1

LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide (LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide)

Metastatic Esophageal; Gastric Cancer · Metastatic Esophageal

#MetastaticEsophageal#Antibody#Phase1#monoclonal-antibody#GastricCancer+1
Trials 1Status Recruiting
ADCLimited DatastaleGilead SciencesPhase 2

LG (Labetuzumab Govitecan, Labetuzumab Govitecan (LG))

Metastatic Colorectal Cancer; Colon Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#ADC#Phase2#antibody-drug-conjugate#ColonCancer+1
Trials 1Status Discontinued
AntibodyLimited DatastaleAbbViePhase 1

Lemzoparlimab (Lemzoparlimab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase1#monoclonal-antibody#AbbVie
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 3

Lenalidomide and rituximab (R2, Lenalidomide and rituximab, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.)

Follicular Lymphoma (FL) · Follicular Lymphoma (FL)

#FollicularLymphomaFL#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Recruiting

71 / 103 pages

← PreviousNext →